Tenofovir alafenamide for hepatitis B: evolution or revolution?
Chronic hepatitis B infection remains a global health burden despite existence of an eff ective vaccine. Infection with chronic hepatitis B and its sequelae lead to almost 800 000 deaths annually.
1 Over the past decades, treatment of chronic hepatitis B has evolved considerably. Treatment with tenofovir disoproxil fumarate achieves viral suppression in more than 90% of patients during continuous therapy and leads to reversal of liver cirrhosis. 2 Unfortunately, since loss of hepatitis B surface antigen (HBsAg) is rarely achieved and might take up to 30 years, treatment with tenofovir disoproxil fumarate is indefi nite. 3, 4 This is a serious problem because tenofovir disoproxil fumarate is associated with renal toxic eff ects and bone mineral density loss during long-term therapy. 5, 6 For a small group of patients, these serious side-eff ects might even necessitate switching to other, and possibly less potent, nucleoside analogues, thus putting patients at risk of complications of chronic hepatitis B. New therapies with a favourable safety profi le are therefore in demand.
Recently, a new prodrug of tenofovir diphosphate has been developed-tenofovir alafenamide. In patients infected with HIV, tenofovir alafenamide showed more potent antiviral activity at a lower dose, with higher intracellular concentrations, and more than 90% lower systemic plasma concentrations of tenofovir diphosphate than did tenofovir disoproxil fumarate. As a result, the most important benefi t of tenofovir alafenamide over tenofovir disoproxil fumarate is that it leads to fewer renal toxic eff ects and less bone mineral density loss, as shown in a previous trial in patients infected with HIV. 7 In The Lancet Gastroenterology & Hepatology, two large randomised controlled non-inferiority trials comparing tenofovir alafenamide with tenofovir disoproxil fumarate are reported by Henry L Y Chan and colleagues 8 and Maria Buti and colleagues 9 for hepatitis B e antigen (HBeAg) positive (n=873) and HBeAg-negative patients (n=425), respectively. They show that, for both HBeAg-positive and HBeAg-negative patients, tenofovir alafenamide was non-inferior to tenofovir disoproxil fumarate in achieving HBV DNA concentrations less than 29 IU/mL after 48 weeks of treatment (371 10 No diff erences in HBeAg or HBsAg loss were observed.
Occasionally in non-inferiority trials, superiority for the primary outcome can be established. One might argue that when a non-inferiority trial does not demonstrate superiority on the primary outcome measure, secondary outcome measures should not be used to suggest superiority of a new drug. Nevertheless, the secondary safety endpoints in these studies are very important given the indefi nite use of the drugs under investigation. Therefore, in both trials the authors analyse renal and bone safety endpoints for superiority. In both HBeAg-positive and HBeAg-negative patients, there was a signifi cantly greater percentage decline in bone mineral density at the hip (-0·10% vs -1·72% in HBeAg-positive patients, and -0·29% vs -2·16% in HBeAg-negative patients) and spine (-0·42% vs -2·29% in HBeAg-positive patients and -0·88% vs -2·51% in HBeAg-negative patients) in patients treated with tenofovir disoproxil fumarate than in those treated with tenofovir alafenamide. The mean increase in serum creatinine was 0·01 mg/dL for tenofovir alafenamide versus 0·03 mg/dL for tenofovir disoproxil fumarate (p=0·02) in HBeAg-positive patients, and 0·01 mg/dL versus 0·02 mg/dL for both groups in HBeAg-negative patients (p=0·32). The creatinine incline seems to stabilise around a very small variation from week 8 to week 48 onwards.
There was a signifi cant diff erence in estimated glomerular fi ltration rate (eGFR) observed in both patient groups for tenofovir alafenamide versus tenofovir disoproxil fumarate: -0·6 mL/min versus -5·4 mL/min in HBeAg-positive patients, -1·8 mL/min versus -4·8 mL/min in HBeAg-negative patients.
In the HBeAg-negative trial, 9 patients in the tenofovir disoproxil fumarate group were older and there was an imbalance in eGFR, with an advantage for the tenofovir alafenamide treatment group. The authors acknowledge this fact, but the creatinine concentrations and eGFR change over time are not adjusted for baseline age, eGFR, or serum creatinine. This is important since it is unknown whether pre-treatment impaired renal function will lead to a more pronounced eGFR decline on treatment. Therefore, especially within these very small margins of error, it seems too early to conclude that tenofovir alafenamide is better for renal function in HBeAg-negative patients after 1 year of therapy. Additionally, it is unclear whether the small diff erences in bone and renal parameters are clinically relevant. In the fi rst trial 11 of tenofovir disoproxil fumarate in patients with chronic hepatitis B, and in the current trials, 8, 9 a serum creatinine increase of more than 0·5 mg/dL and a clearance of less than 50 mL/min were considered clinically relevant. None of the patients in the previous trial reached this endpoint, and none of the patients on tenofovir disoproxil fumarate experienced this in the current trials, except for one patient with substantial comorbidity who received tenofovir alafenamide. A recent long-term follow-up study 12 of the tenofovir disoproxil fumarate registration trial showed less than 2% of patients with a greater than 0·5 mg/dL serum creatinine increase from baseline, and no signifi cant bone mineral density loss at hip or spine after 7 years of follow-up. Although in the short term there seems to be at least a statistically signifi cant diff erence in bone and renal parameters, long-term clinical safety might be similar for tenofovir alafenamide and tenofovir disoproxil fumarate. Even with 90% less plasma activity, renal side-eff ects were also apparent in the tenofovir alafenamide treatment group. Therefore, it remains to be seen what eff ect tenofovir alafenamide has on eGFR and creatinine over time, especially for patients with substantial comorbidity, chronic kidney disease (eGFR <60 mL/min), or even in those with kidney failure (eGFR <15 mL/min). Nonetheless, given the evidence in patients with HIV 7 and these new trials in patients with chronic hepatitis B, the safety profi le of tenofovir alafenamide seems to be very favourable. Further research and long-term and real-world clinical data are needed to be able to defi nitively conclude whether tenofovir alafenamide is safer than tenofovir disoproxil fumarate. For now, these results for tenofovir alafenamide are very exciting, but might be more of an evolution than a revolution.
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